论文部分内容阅读
目的检测肺癌患者血D-二聚体的改变，了解它与肿瘤发展、扩散、预后及疗效的关系。方法检测肺癌患者359例，其中305例为带瘤患者，54例术后2a无复发、转移，分析其血D-二聚体水平在不同分期、病理类型及治疗过程中的异常改变。结果305例肺癌患者的血D-二聚体水平显著高于正常对照组和54例术后无复发、转移患者，且随着肿瘤发展和扩散、转移明显升高；23例小细胞肺癌患者临床治愈时的血D-二聚体水平明显低于疗前和复发时；不同病理类型肺癌患者血D-二聚体水平在局限期和扩散期无明显差异。结论肺癌患者早期就有血D-二聚体的异常升高，其血D-二聚体的异常改变对病情的发展、预后及疗效有重要意义；不同病理类型肺癌的血D-二聚体水平无明显差异。
Objective To detect the change of blood D-dimer in patients with lung cancer and to understand its relationship with tumor development, spread, prognosis and efficacy. Methods A total of 359 patients with lung cancer were examined, of whom 305 were tumor-bearing patients. 54 patients had no recurrence or metastasis 2a after surgery. The blood D-dimer levels were analyzed at different stages, pathological types, and during treatment. Results The blood D-dimer levels in 305 patients with lung cancer were significantly higher than those in the normal control group and 54 patients without recurrence or metastasis after surgery, and were significantly higher with tumor development, proliferation, and metastasis; 23 patients with small cell lung cancer were clinical Blood D-dimer levels were significantly lower than before treatment and at the time of recurrence. Blood D-dimer levels in different pathological types of lung cancer patients did not differ significantly between the time of limitation and diffusion. Conclusions Patients with lung cancer have an abnormal increase of blood D-dimer in the early stage, and abnormal changes in blood D-dimer are important for the development, prognosis and efficacy of the disease; blood D-dimer in different pathological types of lung cancer There is no significant difference in levels.